Background: Traditional palliation for biventricular cyanotic congenital heart lesions often involves staging with systemic-topulmonary arterial shunts to secure pulmonary blood flow (PBF) in the newborn period prior to complete repair. However, shunts may lead to life-threatening events secondary to shunt occlusion or acute coronary steal. They may be associated with morbidity secondary to diastolic runoff, systemic steal and volume loading, and do not provide pulsatile flow which has the potential to promote pulmonary artery (PA) growth. We have alternatively performed modified right ventricular outflow (mRVO) procedures by establishing antegrade right ventricle-to-PA flow. Methods: Retrospective review of data on all patients who underwent the mRVO procedure from 2013 to 2016, including anatomy, number of interstage catheterizations, reoperations, intensive care unit admissions, hypercyanotic episodes, interval to complete repair, and mortality. Results: Seventeen nonconsecutive patients included tetralogy of Fallot (n ¼ 14), pulmonary valve stenosis (n ¼ 2), and 1 with pulmonary atresiaintact septum; 14 had significant branch PA stenosis. Median age of first mRVO procedure was 14 days (range 5-193), and median duration of follow-up was 15.3 months (range 4-47 months). No patients had post-palliation acute hypercyanotic episodes. Nine were admitted to the ICU for persistent interstage hypoxemia, 7 of whom required reintervention prior to complete repair, which was achieved in 11 patients. Two late deaths unrelated to mRVO occurred. Conclusions: The mRVO procedure is a potential option with satisfactory results. It avoids potential shunt-related sudden death. The physiology of the mRVO palliation may provide unique benefits by providing antegrade pulsatile PBF, facilitates catheter interventions, and avoids branch PA distortion and stenosis.
Introduction
Cyanotic biventricular congenital heart disease (CHD) lesions often require palliation prior to complete repair in order to augment or secure pulmonary blood flow (PBF) in the newborn period. [1] [2] [3] [4] Traditionally, systemic-to-pulmonary artery (PA) shunts are placed to either increase or provide the only source of pulmonary flow, in lieu of the more difficult to control flow via a patent ductus arteriosus (PDA). 5 More recently, in lowbirth-weight patients and/or in those with significant aortic arch branching anomalies, systemic-PA shunting is challenging or carries a higher risk of operative or interstage mortality, for which the right ventricle-PA shunt has been advocated with satisfactory results. 6 However, all shunts require postoperative antiaggregant therapy and have associated problems including
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Blalock-Taussig shunt mRVO modified right ventricular outflow PBF pulmonary blood flow BT Blalock-Taussig PA pulmonary artery CHD congenital heart disease PDA patent ductus arteriosus DORV double outlet right ventricle RVOT right ventricular outflow tract PA-IVS pulmonary atresia and intact ventricular septum RV right ventricular PA-VSDMAPCAs pulmonary atresia, ventricular septal defect and major aorto-pulmonary collaterals ongoing hypoxemia and risk of occlusion, which can extend postoperative recovery periods, require reoperation, and be life threatening. 3, 4, [7] [8] [9] In addition to the aforementioned complications, shunt physiology may be suboptimal. If oversized, shunts can contribute to diastolic runoff with compromised coronary and visceral blood flow, leading to extremes of myocardial ischemia and circulatory collapse and less dramatic but serious complications such as necrotizing enterocolitis and acute prerenal failure, 8 though these complications are more common and threatening in univentricular physiology. 3, 4 Furthermore, some evidence suggests that infants with very hypoplastic branch PAs who undergo primary complete repair in infancy may have suboptimal outcomes. 10, 11 One option in those infants is placement of a shunt, although shunts do not provide pulsatile PBF in systole and diastole, and recent evidence suggests that pulsatile PBF may lead to improved PA growth. 12 With this in mind, we have opted to perform a palliative modified right ventricular outflow (mRVO) technique prior to complete repair, previously described by the Paris group of Vouhé and Raisky. 13, 14 As their group, we hypothesize that this staged approach with the mRVO procedure provides more stable postoperative hemodynamics, does not lead to pulmonary hypertension, with homogeneous and potentially improved growth of the PAs, and has an acceptable safety profile. 14 
Patients and Methods
We performed a retrospective, single-center review of all nonconsecutive patients deemed suitable candidates for future biventricular repair who underwent an mRVO procedure from January 2013 through July 2016 at the Children's Heart Center of the University of Mississippi Medical Center. There were no exclusion criteria to attempt the mRVO procedure other than anatomical contraindications such as a major coronary artery crossing the right outflow precluding even a short transannular patch or right ventriculotomy, or a prominent aortic root shoulder over the right outflow in double outlet right ventricle (DORV) with extreme aortic overriding creating a potentially stenotic right ventricular outflow tract (RVOT) baffle. During the same period, anatomic constraints precluding an mRVO procedure led to 15 patients with tetralogy of Fallot, DORV with RVOT, or pulmonary atresia with ventricular septal defect and major aorto-pulmonary collaterals (PA-VSD-MAPCAs) to undergo a modified Blalock-Taussig shunt (BTS) or central shunt. Patients with discontinuous PAs requiring unifocalization procedures concomitant to shunting were not included, as they represent an extreme end of a spectrum related to restrictive PBF, with a heterogeneous decision-making pathway prior to complete repair. During the study period, we did not offer the mRVO procedure for single ventricle physiology. Also, although available through our interventional cardiology team, the treatment protocol purposefully did not include balloon dilatation or stenting of the RVOT or PDA stenting. Study approval was obtained from our hospital's institutional review board, and informed consent was waived given the retrospective methodology.
A modified RVOT procedure is defined as the first operative intervention performed on the RVOT of a patient with cyanosis deemed a suitable biventricular candidate, as a stage to augment PBF by establishing antegrade right ventricular (RV)-PA flow prior to complete repair. We included one patient with pulmonary atresia and intact ventricular septum (PA-IVS) with an adequate initial tricuspid valve z-score undergoing an RV overhaul operation, in order to demonstrate the feasibility of the approach in this distinctly different congenital lesion. Surgical technique included median sternotomy, cardiopulmonary bypass, and beating heart or aortic cross-clamping and cardioplegic arrest to allow an incision into the right outflow tract across the pulmonary annulus. The PDA was ligated in all instances to remove competitive PBF. Adequate antegrade flow into the PAs was achieved by either resecting a platelike pulmonary atretic membrane and/or by resection of infundibular muscle bundles below the valvar level to allow for easy passage of at least a 4-mm probe. Right ventricular outflow reconstruction was completed by transannular patching, using either tanned autologous pericardium or xenopericardium according to surgeon preference, to establish antegrade RV-PA flow ( Figure 1 ). Intraoperative transesophageal echocardiography was used in all patients and documented a peak transannular gradient of at least 40 mm Hg, with oxygen saturations of 75% to 85% on an FIO 2 of 30% to 50%, representing what was targeted as being "balanced, banded ventricular septal defect" physiology.
Baseline and demographic data were obtained for all patients. All patients underwent routine postoperative transthoracic echocardiography. Subsequent echocardiographic studies were obtained during routine or acute clinical visits at the discretion of the primary cardiologist. All echocardiographic and catheterization data were obtained from existing clinical records. Study points of interest included the number and details of prerepair catheterizations and reoperations, prerepair intensive care unit (ICU) admissions and hypercyanotic episodes, time to complete repair, and echocardiographic data. Data were also collected on any major adverse events including procedural complications, emergent reinterventions, stroke, and mortality.
Data Analysis
Data are presented as median + standard deviation, median (range), or frequency percentage of appropriate cohort).
Results
Demographic, historical, and diagnostic features as well as procedural and early postoperative (perioperative through 30 days after surgery) variables are outlined in Tables 1 and 2 . Seventeen nonconsecutive cases were identified: 14 had tetralogy of Fallot, 2 had pulmonary valve stenosis, and 1 had PA-IVS. Fourteen patients had significant branch PA stenosis; 12 of those 14 had diffuse hypoplasia (of which 2 with PA-VSD-MAPCA's), while 2 had focal stenosis. Median age of first mRVO procedure was 14 days (range and median duration of follow-up age was 17.2 months (range 4-47 months). Although the weight and age of a few larger infants would have qualified for primary complete repair of tetralogy of Fallot per routine in our institution, extremely hypoplastic PAs were judged an unfavorable anatomic substrate for a good outcome, hence the decision to palliate with an initial mRVO procedure. No patients had documented postoperative hypercyanotic episodes. Nine patients were admitted to the ICU for persistent hypoxemia, and 7 of them required reintervention prior to complete repair (median number of procedures
No patients presented with heart failure from unrestricted PBF during the interstage or at the time of complete repair.
Seven patients had genetic anomalies and/or heterotaxy syndrome (one patient had both). The 6 genetic syndromes/anomalies included Klinefelter (XXY) syndrome, XYY syndrome, trisomy 21, congenital disorder of glycosylation type 1a, 22q11 deletion syndrome, and one baby with two significantly abnormal genetic defects (a mosaic duplication from 1p13.2 to 1q23.3 and a duplication at chromosome 16p11.2). This last patient also had asplenic heterotaxy.
Follow-up interventions are outlined in Table 3 . Stratification of the analysis demonstrated a difference based on era. Earlier era (January 2013 through April 2015) had differences in the total number of procedures, duration from the initial mRVO procedure to reintervention, and major morbidities. Although the data are not statistically significant (ie, early vs late era, p 0.23 by Fisher exact test and comparison of proportions analysis CI: À17 to 65, p 0.12), the study was underpowered to detect statistically significant differences across the study points of interest. Given the notable variation, results for each era are reported along with the entire cohort. In brief, 11 patients have undergone complete repair. Seven patients required a reintervention, with a median count of one reintervention. Among patients who have undergone complete repair, eight have normal RV pressures and three have only mildly elevated RV pressures related to residual RV outflow obstruction (all had transannular patches). There were three major adverse events with one stroke in a child with a small subdural hemorrhage, with minimal residual deficits. There were two late deaths presumably unrelated to the mRVO procedure, one in a patient with multiple comorbidities including renal and chromosome abnormalities, and the other in a child born prematurely with chronic lung disease who had sudden cardiac arrest when rehospitalized for communityacquired pneumonia. At the time of manuscript submission, 4 remaining survivors are awaiting elective complete repair. During the same period, 14 patients with tetralogy of Fallot, PA-VSD-MAPCA's, or DORV-tetralogy type with unfavorable anatomy to undergo an mRVO procedure underwent a modified BT (n ¼ 7) or central shunt (n ¼ 7). Mean age at the shunt procedure was 52 days (range 4-250), length of stay 16.7 days (range 5-77), and interval to complete tetralogy repair or Rastelli operation 5.1 months (range 7-268 days).
There was one mortality at five days postoperatively (1/ 14¼7.1%), in a baby with spelling tetralogy and known stenosis of the trachea who was referred to our center intubated. He plugged his airway with failure to oxygenate, requiring emergent central cannulation for VA ECMO, a central shunt prior to ECMO decannulation, and eventual withdrawal of support three days after ECMO decannulation for severe neurological damage.
As the focus of the study was not a comparison between the mRVO procedure and systemic-PA shunting, no comparative analysis was performed. The intention to treat (palliate) was primarily an mRVO procedure unless precluded anatomically, and the study goal an attempt at proof of concept regarding safety and efficacy.
Comments
The optimal management strategy of neonates with significant right ventricular obstructive lesions remains in equipoise. [15] [16] [17] In biventricular defects such as tetralogy of Fallot or pulmonary atresia where staged management would be an option rather than the rule, some authors advocate the use of an initial palliative shunt followed by deferred complete repair, whereas others advocate initial complete repair. 18 These decisions depend on multiple factors related to both the patient and the heart center. Our institutional protocol has been to stage the procedures and not perform primary complete repair in severely cyanotic neonates or small infants. During this study period, although available, in concert with our interventional cardiologists, we chose not to perform interventional catheter perforation of an atretic pulmonary valve, balloon dilate or stent the right outflow, or implant a PDA stent. Given this protocol, the presented data add to existing information that demonstrates the mRVO procedure to be an attractive alternative palliation with satisfactory results. In the largest series to date, the Paris group of Vouhé and Raisky performed the mRVO procedure in 109 patients with PA-VSD and diminutive PAs, with an early mortality of 2.7%, an interstage attrition of 6.6%, and successful biventricular repair in 84 (77%) patients, with 8 still awaiting repair.
14 Significant growth of the native PAs was documented, despite the need for 29 reinterventions for restrictive PBF and 28 (33%) late reoperations. Although the late morbidity rate was significant, they advocate the palliative approach for this particularly challenging subset of patients, citing the low early mortality, adequate PA growth, and high success rate of achieving biventricular repair. 14 The BT shunt (BTS) and its modifications have been the traditional initial palliation for cyanotic infants. In general, shunts are placed in smaller weight neonates or in those with an indication for an emergent intervention 19, 20 as a bridge to full repair. Recognizing their revolutionary contribution to the field of congenital heart surgery, these shunts have complications. First, the BTS is prone to occlusion and portends a relatively prolonged postoperative course and high rate of in-hospital and interstage mortality. 21 Second, regulation of shunt flow is difficult to control, with some variability in terms Total cardiac procedures of shunt size and oftentimes very reactive pulmonary vasculature. Some centers prefer 3.5 shunts on all neonates, while others place 3.0-, 3.5-, or 4.0-mm shunts based on infant weight and other factors. 22, 23 This imprecise flow regulation can result in either deficient or excess PBF. 24 Excess flow can contribute to atrioventricular valve regurgitation as a result of increased ventricular end-diastolic volume, systemic, and coronary steal. Furthermore, shunt flow can increase as the infant's pulmonary vascular resistance decreases, resulting in worsening diastolic runoff, contributing to decreased coronary perfusion pressure with cardiac dysfunction, renal failure, and necrotizing enterocolitis. 25 On the other hand, inadequate shunt flow may lead to recurrent hypoxemia/cyanosis, an increased risk of thrombosis, and potentially inadequate PA growth. Shunt dysfunction, including acute thrombosis and obstruction, has been described in up to 40% of patients. 26 Recent literature notes mortality as high as 10%, with the presumption that the majority of deaths were, at least in part, related to shunt dysfunction or thrombosis or coronary steal. 25 Shunts have additional anatomic issues including branch PA distortion, stenosis, and even segmental branch occlusion. Data suggest that adverse events occur more frequently in shunted patients with smaller PAs. 27 These anatomic PA problems can necessitate reinterventions and potentially affect long-term prognosis if a significant anatomic problem is refractory to therapy. In addition, shunts do not decompress the RV. The RV is particularly sensitive to increased afterload which can cause subendocardial ischemia and eventual fibrosis. 28 This, in turn, can adversely affect postrepair recovery and long-term ventricular function.
Given this clinical setting, our current preferred practice is to perform an initial palliation utilizing an mRVO procedure with subsequent repair in all neonates when there are no anatomic contraindications; the approach seems even more justified or attractive for the subset of high-risk patients with multiple noncardiac comorbidities, genetic syndromes, prematurity, very low weight, or significantly hypoplastic pulmonary artery anatomy that may increase morbidity and mortality with early repair. 29, 30 Not surprisingly, we observed an era effect, with fewer major complications in the recent era. We believe this is largely due to improvements in our technique that were refined over time. Nevertheless, analysis of the crude dataincluding the early era-demonstrates that the technique has satisfactory outcomes. Accordingly, certain heart centers with fewer resources or staff coverage on night/weekend shifts may prefer mRVO physiology over shunted circulation.
The modified RVOT approach has a few technical elements that deserve highlighting. One primary issue is the importance of an appropriately sized transannular patch or infundibulotomy. Broad connections can be adjusted with a hemostatic clip or U-stitch, whereas an infundibulotomy should carefully be controlled by performing the muscle bundle resection with some degree of precision. 13, 14 Along these lines, our data demonstrated an era effect, predominantly related to a "learning curve". Even in the more recent era, two of our patients required RVOT stenting; as with the Paris group, our approach moving forward will be to err even more on a wider connection with less residual RVOT gradient, recognizing that patients may develop pulmonary overcirculation which would be easy to manage postoperatively. We have not observed this to date, and pulmonary overcirculation was only noted in less than 1% of the Paris series, who currently advocate leaving as large as a 6-mm opening for babies weighing 3.5 kg. 14 We hope that larger connections, as suggested by the Paris group, will reduce our rate of interstage need for reintervention. Right outflow morphology is an important determinant of the surgical approach, as an infundibulotomy may be contraindicated in patients with long-segment pulmonary atresia or anomalous coronary anatomy across the right outflow, necessitating RV-PA conduit placement. 6, 31 Theoretical disadvantages of the mRVO technique include the need for cardiopulmonary bypass (with or without cardioplegia) and sacrificing the pulmonary valve in patients with tetralogy of Fallot, which could otherwise eventually grow and be spared at the time of deferred complete repair.
Our study has multiple limitations. We provide a descriptive analysis and retrospective methodology with those inherent limitations. Our sample size is small, in a patient population with a wide spectrum of anatomic variability, hence limiting generalization with regard to applicability. We did not measure indexed PA growth prior to palliation and after complete repair to confirm adequate PA growth, but suggest the success of the approach by the high number of complete repairs achieved, with normal or near-normal RV pressures at latest follow-up. There was an era effect as we refined our surgical technique, and the arbitrary variability in era duration and corresponding follow-up interval may influence the interpretation of results. Further data with standardization of surgical technique across a more homogenous patient population are necessary to obtain measures of association.
Conclusion
The mRVO is a palliative procedure to augment pulmonary blood flow in critical patients with cyanosis deemed unsuitable for initial complete repair. The technique avoids issues related to potentially life-threatening cyanosis from acute shunt occlusion, shunt-related PA distortion, and parallel circulations. Our experience shows the mRVO procedure to be safe and effective. We are hopeful that more experience with larger mRVO connections may reduce the need for interstage reinterventions.
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